On October 18, 2023 PharmaMar (MSE:PHM) reported that it will present new data on lurbinectedin in Small Cell Lung Cancer (SCLC) at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) congress, being held in Madrid from October 20-24th (Press release, PharmaMar, OCT 18, 2023, View Source [SID1234636111]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Among the most outstanding studies will be an oral presentation by Dr. Antonio Calles, where final data from the LUPER trial of lurbinectedin in combination with pembrolizumab (immunotherapy) in second-line SCLC will be presented. The presentation called "Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the phase 1/2 LUPER study" concludes that the combination of lurbinectedin and pembrolizumab is an effective second-line treatment for SCLC in patients who did not receive prior immunotherapy, achieving in some cases deep and durable responses, with a manageable safety profile and no new emerging signs of toxicity when combining the two drugs.
Dr. Antonio Calles, Specialist in Medical Oncology at the Hospital General Universitario Gregorio Marañón, Madrid, Spain, who has led the study, comments "the combination represents an opportunity for those patients with metastatic SCLC, who could not be treated with first-line immunotherapy. The treatment achieved a confirmed response rate of 46.4%, including deep and durable responses that exceeded one year in some patients. Median Progression-Free Survival (PFS) was significantly longer for platinum-sensitive patients compared to platinum-resistant patients, with a PFS of 10 versus3 months, respectively. Currently, the only treatment other than lurbinectedin approved for this indication in the last 2 decades, has a response rate of only ~20% and a PFS of 4 months, in addition to very significant toxicity. However, here we saw no unexpected side effects both drugs could be safely combined at full doses".
Dr. Ali Zeaiter, Vice President and Head of Clinical Development at PharmaMar said: "We are pleased to present new data on the combination of lurbinectedin with immunotherapy. We believe that these data, with the suggested improvements in patients’ outcomes, confirm once again that lurbinectedin is an important treatment option for relapsed SCLC and support the ongoing investigation of lurbinectedin combination with immunotherapy".
In addition to the above presentation, the study entitled "A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study" will show the final Overall Survival (OS) data for the combination of doxorubicin and trabectedin of 33.1 months versus 23.8 months for doxorubicin alone. These data confirm that this is the first drug combination that is able to demonstrate benefit in both PFS and OS in a phase III trial in first-line treatment of metastatic leiomyosarcoma. These data have supported further the rationale of also studying lurbinectedin in sarcoma.
Lead investigator, Dr. Patricia Pautier, from the Institut Gustave Roussy in Villejuif, Paris, France, comments "the final results were positive with a median progression-free survival (PFS) statistically improved from 6.2 months with doxorubicin alone to 12.2 months with the combination."
PharmaMar’s abstracts at ESMO (Free ESMO Whitepaper) 2023
PRODUCT TITLE LEAD AUTHOR ABSTRACT
Zepzelca (lurbinectedin) Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): the phase 1/2 LUPER study Dr. Antonio Calles Mini oral presentation ABSTRACT: 1989MO DATE: Saturday, October 21st, 14:50 – 14:55 CET
Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor Dra. Irene Moreno ABSTRACT: 679P DATE: Monday, October 23rd
Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: a review on the basis of clinical trials Dr. Manuel Domine ABSTRACT: 2024P DATE: Saturday, October 21st
Yondelis (trabectedin) A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study Patricia Pautier Proffered Paper presentation ABSTRACT: #2965 DATE: Sunday, October 22nd, 08:30-10:00 CET
TOMAS2: a randomized phase 2 study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments. Lorenzo D’Ambrosio Proffered Paper presentation ABSTRACT: #4076 DATE: Sunday, October 22nd, 08:30-10:00 CET.
Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC) – GEICO 105-O Study María Jesús Rubio ABSTRACT: 770P DATE: Sunday, October 22nd
Trabectedin plus radiotherapy on symptomatic advanced sarcoma patients, results from the SYNERGIAS study: a Spanish group for research in sarcoma (GEIS) phase II study Javier Martin Broto ABSTRACT: 1926P DATE: Monday, October 23rd
Targeting Microenvironment and Cellular Immunity in Sarcomas with Trabectedin Combined With Metronomic Cyclophosphamide: The TARMIC study Cheng-Ming Su ABSTRACT: 1924P DATE: Monday, October 23rd